Pyxis Oncology director granted 45,867 stock options

Pyxis Oncology, Inc. director Rachel Humphrey received a grant of stock options covering 45,867 shares of common stock.

Accepted by SEC EDGAR 03/25/2026 - 05:05 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Pyxis Oncology, Inc. director Rachel Humphrey received a grant of stock options covering 45,867 shares of common stock. The options have an exercise price of $1.36 per share and were awarded at no cost to her.

The filing states that all 45,867 options will vest 100% on the first anniversary of the March 24, 2026 grant date, as long as she continues in service through that date. Following this award, her reported derivative holdings from this grant total 45,867 stock options.

Insider Trade Summary

Grant/Award: 45,867 shares

Grant/Award 1 txn

Insider HUMPHREY RACHEL

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	45,867	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 45,867 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Pyxis Oncology (PYXS) director Rachel Humphrey report in this Form 4?

Rachel Humphrey reported receiving a stock option grant for 45,867 shares of Pyxis Oncology common stock. The options were granted at no cost and represent a compensation-related award, not an open-market purchase or sale of existing shares.

How many Pyxis Oncology (PYXS) options were granted to Rachel Humphrey and at what price?

She received options to acquire 45,867 shares of Pyxis Oncology common stock at an exercise price of $1.36 per share. This means she can later buy those shares at $1.36, subject to the options vesting on the stated schedule.

When do Rachel Humphrey’s Pyxis Oncology (PYXS) stock options vest?

The options vest 100% on the first anniversary of the grant date. Vesting is conditioned on her continued service with Pyxis Oncology through that one-year vesting date, as specified in the Form 4 footnote.

Is the Pyxis Oncology (PYXS) Form 4 a market buy or sell by Rachel Humphrey?

No, it is not a market buy or sell. The Form 4 reports a grant of stock options as compensation, coded “A” for award, with no purchase price paid on the grant date and no sale of existing common shares.

How many Pyxis Oncology (PYXS) options does Rachel Humphrey hold after this transaction?

After this reported transaction, her holdings from this grant total 45,867 stock options. The Form 4 shows 45,867 derivative securities following the transaction, all tied to Pyxis Oncology common stock as the underlying security.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HUMPHREY RACHEL

(Last) (First) (Middle)

C/O PYXIS ONCOLOGY, INC.

321 HARRISON AVENUE, 11TH FL. SUITE 1

(Street)

BOSTON MASSACHUSETTS 02118

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pyxis Oncology, Inc. [ PYXS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.36	03/24/2026		A		45,867		(1)	03/24/2036	Common Stock	45,867	$0	45,867	D

Explanation of Responses:

1. The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.

	/s/ Jitendra Wadhane, Attorney-in-Fact for Rachel Humphrey	03/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)